In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Brought to you by

Adnexus uses PROfusion to give BMS cancer candidates

Executive Summary

Protein medicines developer Adnexus Therapeutics has agreed to use its PROfusion system to discover preclinical Adnectin drug candidates against up to six cancer targets for Bristol-Myers Squibb.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Alliance
    • Co-Promotion
    • R&D and Marketing (Licensing)

Related Companies

UsernamePublicRestriction

Register